January 2025 in “Journal of the American Academy of Dermatology” Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.
The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.
39 citations
,
February 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil safely treats hair loss, with hypertrichosis as main side effect.
6 citations
,
January 2025 in “RSC Medicinal Chemistry” Targeting the RAAS with small molecules can improve cardiovascular disease treatments.
3 citations
,
November 2025 in “Annals of Medicine” Following the DASH diet reduces mortality risk in hypertensive adults.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
17 citations
,
June 2019 in “Cellular signalling” Minoxidil helps protect and rebuild elastic fibers in arteries, improving artery function, especially in older females.
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
January 2022 in “Springer eBooks” February 2026 in “Journal of the American Academy of Dermatology” The combination of spironolactone and low-dose minoxidil is generally safe for treating hair loss in adult females, with mostly mild side effects.
October 2007 in “Inpharma Weekly”
Low-dose oral minoxidil is safe and effective for treating hair loss, with most side effects being mild and reversible.
7 citations
,
November 2020 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil may cause side effects like hypertrichosis and is not suitable for everyone.
March 2002 in “Clin-Alert” In 2002, various drugs caused serious side effects, including vitamin B12 deficiency, heart issues, blindness, hypersexuality, allergic reactions, blood clotting problems, pupil dilation, capillary leak syndrome, muscle breakdown, hepatitis, skin reactions, and lupus.
5 citations
,
January 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil is an effective and safe treatment for hair loss.
1 citations
,
June 2024 in “International Journal of Dermatology” Avoid alcohol when taking low-dose minoxidil to prevent severe hangovers.
March 2025 in “Journal of Clinical Medicine” Low-dose oral minoxidil effectively treats alopecia but can cause side effects like excess hair growth and fluid retention.
July 2024 in “Heart Lung and Circulation” Age, diabetes, and cardiogenic shock at PCI are key factors linked to in-hospital death in STEMI patients with hypertension.
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
March 2025 in “Actas Dermo-Sifiliográficas” High-dose oral minoxidil can improve hair growth but may cause side effects.
October 2019 in “UNESP Institutional Repository (São Paulo State University)” Oral minoxidil 1 mg is effective and safe for female hair loss, with less shedding but more hair growth on the body.
July 2021 in “Indian journal of drugs in dermatology” Combining minoxidil with MS injections leads to better hair regrowth in men.
15 citations
,
October 1981 in “Archives of internal medicine” Minoxidil can cause severe skin reactions like Stevens-Johnson syndrome in rare cases.
Minoxidil overdose can cause serious side effects, and users should be educated on its safe use.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
January 2024 in “Wiadomości Lekarskie” New devices may treat heart failure more effectively than drugs.
September 2024 in “Journal of the American Academy of Dermatology” Experts agree on guidelines for safely using low-dose oral minoxidil to treat hair loss.
1 citations
,
October 1974 in “Postgraduate medicine” New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
January 1987 in “Chronica Dermatologica”
December 2025 in “Cell Communication and Signaling” Minoxidil may help treat myelodysplastic syndrome without harming normal blood cell production.